Pharma News

Danicamtiv, what is the likelihood that the drug will be approved?

Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Danicamtiv’s likelihood of approval (LoA) and phase transition for Atrial Fibrillation took place on 11 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Danicamtiv Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Danicamtiv overview

Danicamtiv (MYK-491, DCM-1) is under development for the treatment of dilated cardiomyopathy (DCM), atrial fibrillation and systolic heart failure. It is a new molecular entity which is administered through oral route as a suspension and tablet. It is developed based on MyoKardia’s drug discovery platform.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Danicamtiv LOA Data

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
Key Developers
Highest Development Stage

Source link
#Danicamtiv #likelihood #drug #approved

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *